RT Conference Proceedings
T1 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
A1 Stratigos, A. J.
A1 Sekulic, A.
A1 Peris, K.
A1 Bechter, O.
A1 Dutriaux, C.
A1 Kaatz, M.
A1 Lewis, K. D.
A1 Basset-Seguin, N.
A1 Chang, A. L. S.
A1 Dalle, S.
A1 Fernandez-Orland, A.
A1 Licitra, L.
A1 Robert, C.
A1 Ulrich, C.
A1 Hauschild, A.
A1 Migden, M. R.
A1 Dummer, R.
A1 Li, S.
A1 Bowler, T.
A1 Fury, M. G.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/27616
UL https://hdl.handle.net/10668/27616
LA en
DS RISalud
RD Apr 9, 2025